Evaluation of modified hyaluronic acid in terms of rheology, enzymatic degradation and mucoadhesion.


Journal

International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578

Informations de publication

Date de publication:
15 Feb 2019
Historique:
received: 31 07 2018
revised: 30 10 2018
accepted: 18 11 2018
pubmed: 23 11 2018
medline: 23 4 2019
entrez: 23 11 2018
Statut: ppublish

Résumé

This study aimed to investigate the properties of modified hyaluronic acid in terms of rheological properties, enzymatic degradation and mucoadhesiveness. Hyaluronic acid (HA) was chemically modified with sulfhydryl ligand cysteine ethyl ester (C) in order to immobilize sulfhydryl groups on the polymeric backbone. MTT assay was performed to evaluate the safety of hyaluronic acid-cysteine ethyl ester (HAC). Rheological and enzymatic degradation studies were accomplished by preparing hydrogels of HA and HAC, respectively. HA served as control. Enzymes such as lysozyme, amylase and hyaluronidase were chosen to perform degradation studies. To study mucoadhesiveness, hydrogels of HA and HAC, respectively, were mixed with mucus and evaluated by rheology. MTT assay indicated no toxicity at all. The rheological assay showed 2.2-fold increase in gelling properties in case of HAC in comparison to HA. Furthermore, it could be shown that HAC was degraded by amylase to a lesser extent of 11.5-fold than HA. After 2 h, HA showed a higher degradation by lysozyme with 67.97% than HAC. Adhesion studies exhibited a 2.17-fold higher mucoadhesion of HAC with mucus compared to HA. These results will open the door for high efficient drug delivery systems based on hydrogels for mucosal application.

Identifiants

pubmed: 30465836
pii: S0141-8130(18)33973-4
doi: 10.1016/j.ijbiomac.2018.11.186
pii:
doi:

Substances chimiques

Enzymes 0
Oxidants 0
Hyaluronic Acid 9004-61-9
Iodine 9679TC07X4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1204-1210

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Flavia Laffleur (F)

University of Innsbruck, Institute of Pharmacy, Department of Pharmaceutical Technology, Innrain 20-82, 6020 Innsbruck, Austria; Massachusetts Institute of Technology, Koch Institute for Integrative Cancer Research at MIT, Langer Lab, 77 Massachussets Ave, Cambridge, MA 02139, USA. Electronic address: Flavia.Laffleur@uibk.ac.at.

Kesinee Netsomboon (K)

University of Innsbruck, Institute of Pharmacy, Department of Pharmaceutical Technology, Innrain 20-82, 6020 Innsbruck, Austria; Division of Pharmaceutical Sciences, Faculty of Pharmacy, Thammasat University, Rangsit campus, Phahonyothin Rd., Khlong Luang, Pathumthani 12120, Thailand.

Liliana Erman (L)

University of Innsbruck, Institute of Pharmacy, Department of Pharmaceutical Technology, Innrain 20-82, 6020 Innsbruck, Austria.

Alexandra Partenhauser (A)

University of Innsbruck, Institute of Pharmacy, Department of Pharmaceutical Technology, Innrain 20-82, 6020 Innsbruck, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH